Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: CRIS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.45M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 5 | Beta 4.01 | 52 Weeks Range 1.02 - 4.50 | Updated Date 12/5/2025 |
52 Weeks Range 1.02 - 4.50 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -1.31 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) -218.01% |
Management Effectiveness
Return on Assets (TTM) -61.2% | Return on Equity (TTM) -2951.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9078066 | Price to Sales(TTM) 1.5 |
Enterprise Value 9078066 | Price to Sales(TTM) 1.5 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 12928853 | Shares Floating 11165745 |
Shares Outstanding 12928853 | Shares Floating 11165745 | ||
Percent Insiders 6.99 | Percent Institutions 35.69 |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Founded in 2000, the company has transitioned from a drug discovery platform company to focusing on clinical-stage development.
Core Business Areas
- Drug Development: Curis focuses on developing and commercializing drug candidates targeting cancer treatment. This includes clinical trials, regulatory submissions, and potential commercialization efforts.
- Collaboration and Licensing: Curis enters into collaboration and licensing agreements with other pharmaceutical companies to develop and commercialize its drug candidates. This includes sharing development costs and revenues.
Leadership and Structure
Curis Inc's leadership team consists of the Chief Executive Officer, Chief Medical Officer, and other key executives. The organizational structure involves departments for research and development, clinical operations, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Emavusertib: Emavusertib (CA-4948) is an oral IRAK4 inhibitor being developed for the treatment of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and Waldenstromu2019s macroglobulinemia (WM). Market share data is not publicly available. Competitors include companies developing therapies for B-cell lymphomas such as AbbVie, Roche, and Gilead Sciences.
- Fimepinostat: Fimepinostat, an HDAC inhibitor, was previously being developed for various cancers, including lymphoma and myeloma. Development has been discontinued. It had no associated market share or current revenue.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. It's a competitive landscape with numerous companies developing novel therapies for cancer and other diseases.
Positioning
Curis is a smaller biotechnology company focused on targeted cancer therapies. Its competitive advantage lies in its IRAK4 inhibitor, emavusertib. However, it competes with larger pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The global B-cell lymphoma market is projected to reach billions of dollars. Curis, with emavusertib, is positioned to capture a portion of this market if the drug is approved and effectively commercialized.
Upturn SWOT Analysis
Strengths
- Novel IRAK4 inhibitor (emavusertib)
- Potential for targeted cancer therapy
- Strategic collaborations for development and commercialization
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trials and regulatory approvals
- Single lead product exposes the company to risks
- History of discontinued programs impacting investor confidence.
Opportunities
- Positive clinical trial results for emavusertib
- Partnerships for broader development and commercialization
- Expansion into new cancer indications
- Orphan drug designation for rare cancer types
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established therapies and larger pharmaceutical companies
- Patent expirations and generic competition
Competitors and Market Share
Key Competitors
- ABBV
- RHHBY
- GILD
- MRK
Competitive Landscape
Curis faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its IRAK4 inhibitor technology, but clinical trial success is crucial.
Growth Trajectory and Initiatives
Historical Growth: Curis' growth has been dependent on successful clinical trials and partnerships. Historical performance has been inconsistent.
Future Projections: Future growth projections depend on the success of emavusertib and potential new partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing on the development of emavusertib and seeking partnerships to advance its clinical programs.
Summary
Curis Inc is a high-risk, high-reward biotechnology company focused on developing cancer therapies. Its lead product, emavusertib, shows promise, but clinical trial results are critical. The company's limited financial resources and dependence on successful partnerships are key challenges it needs to address to create value and mitigate risk.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, SEC reports, Analyst reports, Press releases.
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.curis.com |
Full time employees 34 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.